QR Code

Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population

Abstract Background Lenvatinib is a multitargeted tyrosine kinase inhibitor that is being tested in combination with immune checkpoint inhibitors to treat advanced gastric cancer; however, little data exists regarding the efficacy of lenvatinib monotherapy. Patient-derived xenografts (PDX) are estab...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: John D. Karalis, Lynn Y. Yoon, Suntrea T. G. Hammer, Changjin Hong, Min Zhu, Ibrahim Nassour, Michelle R. Ju, Shu Xiao, Esther C. Castro-Dubon, Deepak Agrawal, Jorge Suarez, Scott I. Reznik, John C. Mansour, Patricio M. Polanco, Adam C. Yopp, Herbert J. Zeh, Tae Hyun Hwang, Hao Zhu, Matthew R. Porembka, Sam C. Wang
Hōputu: Artigo
Reo:Inglês
I whakaputaina: BMC 2022-03-01
Rangatū:Journal of Translational Medicine
Ngā marau:
Gastric cancer
Patient-derived xenograft
PDX
Lenvatinib
NSG mice
Nude mice
Urunga tuihono:https://doi.org/10.1186/s12967-022-03317-7
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite